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Background:  Inflammation plays an important role in the postoperative morbidity of organs, which is related to 
the activation of pro-inflammatory and anti-inflammatory cytokines.  Ulinastatin (Urinary trypsin inhibitor, UTI) is 
a serine protease inhibitor found in human urine or serum that inhibits the activation of human leukocyte elastase.   
This study examined the effect of UTI on the inflammation response in patients undergoing a gastrectomy.
Methods:  Thirty patients scheduled to undergo a gastrectomy were divided into two groups as follows: Control 
group (untreated, n = 15) and UTI group (100,000 units of UTI were continuously injected intravenously for 2 hours, n 
= 15).  Arterial blood was sampled before surgery (T0), 10 minutes after its onset (T1), at its end (T2), and 1 hour after 
surgery (T3) to measure the level of cytokines. 
Results:  Both the control and treatment groups had higher interleukin (IL)-6 levels at T2 and T3 than T0, and 
the level increased with time.  However, the increase was smaller in the treatment group.  The IL-8 levels were not 
activated significantly in any of the groups.
Conclusions:  UTI inhibits the secretion of IL-6, which is an inflammatory cytokine produced after a gastrectomy.   
This shows that UTI can decrease the inflammation reaction caused by surgical stress.  (Korean J Anesthesiol 2010; 
58: 334-337)
Key Words:  Gastrectomy, Inflammatory cytokine, Interleukin-6, Urinary trypsin inhibitor.
Effect of ulinastatin on cytokine reaction during gastrectomy
Ji Hun Park, Sang Hyun Kwak, Cheol Won Jeong, Hong Beom Bae, and Seok Jai Kim
Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School, Gwangju, Korea
Received: October 21, 2009.  Revised: November 17, 2009.  Accepted: February 18, 2010.
Corresponding author: Sang Hyun Kwak, M.D., Ph.D., Department of Anesthesiology and Pain Medicine, Chonnam National University 
Medical School, 671, Jebong-no, Dong-gu, Gwangju 501-757, Korea. Tel: 82-62-220-6893, Fax: 82-62-232-6294, E-mail: shkwak@jnu.ac.kr
This study was financially supported by Chonnam National University, 2008.
    This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
CC335 www.ekja.org
Korean J Anesthesiol Park, et al.
Introduction
    The stress response to surgery or inflammation is mediated by 
complex interactions. Cytokines, such as tumor necrosis factor 
alpha (TNF-α), Interleukin (IL)-1, and IL-6, as well as other 
humoral mediators of inflammation, are potent activators of the 
central stress-responsive neurotransmitter systems. 
    The stress responses to surgery and inflammation activate 
a systemic inflammatory response characterized clinically by 
changes in a variety of functions, such as nervous, endocrine, 
immune, and hematopoietic systems [1]. The systemic inflam-
matory response is maintained by a range of factors, including 
cytokine production. The overproduction of pro-inflammatory 
cytokines and the inappropriate release of anti-inflammatory 
cytokines during surgery can harm the organs [2]. The pro-
inflammatory cytokine, IL-6, is a sensitive marker of tissue 
injury, and has been associated with invasiveness and the 
duration of surgery [3]. 
    Urinary trypsin inhibitor (UTI), a serine protease inhibitor, 
is used widely in patients with inflammatory disorders, 
including shock and pancreatitis. It suppresses the human leu-
kocyte elasetase activity and inhibits the production of pro-
inflammatory cytokines, such as TNF- α and IL-8 [4,5].
    The circulating concentration of pro-inflammatory cytokines, 
IL-6 and IL-8, were measured in patients undergoing a gastrec-
tomy, with and without UTI infusion.
Materials and Methods
    Thirty patients undergoing a gastrectomy under general 
anesthesia were studied. There were no differences in age, 
gender, weight, and height between the groups (Table 1). All 
patients provided written informed consent and the study was 
approved by the Institutional Review Board for Human Studies. 
Those scheduled to undergo a re-operation, as well as those 
with infectious diseases or a history of chronic obstructive 
pulmonary disease (COPD) were excluded. 
    After at least 8 hours of fasting, the participants were given 
midazolam 0.1 mg/kg orally, 1 hour before the induction 
of anesthesia. When the patients arrived at the operating 
room, a noninvasive blood pressure, ECG, pulse oximetry, 
and bispectral index monitor (BIS XP monitor A 2000, Aspect 
Medical System Inc., Natick, MA, USA) was attached. The 
arterial pressure was measured continuously through a 20 gauge 
catheter that had been inserted into the radial artery before the 
induction of general anesthesia. Anesthesia was induced using 
IV injections of 1% propofol (2 mg/kg) and rocuronium (1-2 
mg/kg). Anesthesia was maintained with sevoflurane and 50% 
N2O in oxygen. The sevoflurane level was adjusted so that the 
bispectral index would maintain a level of 40-60.
    After inducing anesthesia, the patients were assigned randomly 
to 2 groups; the UTI treatment group (n = 15) and control group 
(n = 15). During surgery, the treatment group received 100,000 
units of UTI intravenously over the following 2 hours, while 
nothing was given to the control group. To observe the changes 
in the level of inflammatory cytokines (IL-6 and IL-8), blood 
samples were taken from the radial artery before surgery (T0), 
10 minutes after its onset (T1), at its end (T2), and 1 hour post-
surgery (T3).
    The patient’s blood (3 ml) was centrifuged at 4
oC and the 
serum was stored at -70
oC. The arterial pressure and heart rate 
at the time of sampling were recorded, and the amount of blood 
loss, volume of fluids and transfusions administered, total time 
under anesthesia, and duration of surgery were also recorded. 
In addition, liver function tests (aspartate transaminase [AST], 
alanine transaminase [ALT]) and renal function tests (blood 
urea nitrogen [BUN], creatinine [Cr]) were performed before 
and after surgery.
    The IL-6 and IL-8 levels were measured using an Enzyme-
linked immunosorbent assay (ELISA) kit (R&D system, Minnea-
polis MN, USA), and the values are expressed as the mean ± SD. 
SPSS (version 15.0, SPSS Inc, Chicago, USA) was used for the 
statistics. An independent sample t-test was used to compare 
the demographic data, time, fluid, blood loss and laboratory 
data. The time series changes in the IL-6 levels were analyzed 
by repeated measure analysis within the groups and a Mann-
Whitney test between the groups. A P value <0.05 was con-
sidered significant.
    Group sample sizes of 13 and 13 were considered necessary 
to achieve an 80% power to detect a difference of 25.0 between 
the null hypothesis that both group means are 45.7 and the 
alternative hypothesis that the mean of group 2 is 20.7 with 
estimated group standard deviations of 26.8 and 10.5 and a 
significance level (alpha) of 0.05 using a two-sided Mann-Whitney 
test assuming a normal distribution.
Table 1.  Demographic Data, Time, Fluid and Blood Loss
Control
(n = 15)
UTI
(n = 15)
Age (yr)
Weight (kg)
Sex (Male/Female)
Duration of Anesthesia (min)
Duration of surgery (min)
Fluid input (ml)
Blood loss (ml)
54 ± 7
61 ± 9
22/8
171 ± 76
156 ± 76
2,920 ± 645
  580 ± 185
58 ± 9
  60 ± 14
  20/10
179 ± 27
164 ± 27
2,655 ± 664
  478 ± 148
Values are reported as the mean ± SD or number of patients. UTI: 
urinary trypsin inhibitor.336 www.ekja.org
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Results
    The intraoperative characteristics, such as the duration of 
surgery and anesthesia, blood loss, and total amount of the fluid 
given, were comparable (Table 1). The serum concentrations of 
IL-6 were higher in both groups at T2 and T3 than at T0, but the 
degree of these increases was significantly smaller in the UTI 
group than in the control group. The serum concentrations of 
IL-8 increased significantly in the control group, but not in the 
UTI group at T2 and T3 compared with T0 (Table 2).
    There was an increase in the postoperative hepatic enzymes 
involving AST and ALT compared to the preoperative values in 
the control group, but not in the UTI group (Table 3).
Discussion
    The main result of this study is that UTI attenuates the 
production of IL-6 by surgical stress. 
    The serum level of IL-6 is a sensitive marker of tissue damage. 
The level increased in response to surgical stimuli and the 
maximal level was affected by the duration of surgery [3]. IL-6 
is related directly to the appearance of endotoxins. Endotoxin 
is referred to as lipopolysaccharide (LPS), which activates 
the complements or cytokines, and is an important cause of 
the systemic inflammatory responses [6]. In addition, IL-6 
causes acute reactions in the liver [7], acts as an endogenous 
pyrogen [8], and stimulates the secretion of polymorphonuclear 
leukocyte elastase (PMNE), which causes sepsis or acute 
respiratory distress syndrome [9-11]. The reactions mentioned 
above are inhibited by UTI [11].
    In humans and animal models of systemic inflammation, 
TNF-α, IL-6 and IL-8 are released sequentially, causing 
inflammation cascades. IL-1 and TNF-α can induce the 
expression of IL-8 in the transcription phase, in cells, such as 
the endothelial cells and monocytes in the blood [12-14]. This 
IL-8 promotes tissue injury by neutrophil infiltration and the 
secretion of the lysosomal enzymes along with the peroxide 
anions [15]. 
    In this study, the post-operative IL-6 and IL-8 levels were 
higher than the levels checked before surgery. The post-
operative IL-6 level was increased significantly in both groups 
but the degree of the increase in the treatment group was 
attenuated. The post-operative IL-8 level of the control group 
increased significantly, but the treatment group did not show 
such marked changes. In addition, there were no significant 
differences between the IL-8 levels in the two groups. The IL-8 
levels have relatively large standard deviations and the mean 
values are <2 pg/ml. The mean minimum detectable dose of 
the IL-8 ELISA kit was 3.5 pg/ml, which means that these IL-8 
values should be rejected. Previous studies reported that the 
IL-8 levels ranged from several tens to several hundred after 
surgery, such as cardiac surgery and aortic surgery [16,17]. 
These results indicate some differences in the intensity of stress 
between procedures. The IL-8 levels are expected to increase 
along with IL-6 because it also is an inflammatory cytokine. 
However, this was not observed in this study.
    UTI is a glycoprotein stable in both heat and acids, and is a 
serine protease inhibitor found in human urine or blood. UTI 
is secreted when inter-α-trypsin inhibitors are degraded by 
neutrophilic elastases [18]. UTI has many physiological effects, 
including the inhibition of neutrophilic elastase, trypsin, α -chymo-
trypsin, plasmin, and cathepsin G. Previous studies showed that 
UTI inhibits proinflammatory substances, such as IL-8, which 
is induced by neutrophilic elastase in human bronchoepithelial 
cells [4]. Studies have also found that UTI inhibits TNF-α 
from monocytes, intracellular adhesion molecule-1 (ICAM-1) 
induced by LPS, and the infiltration of neutrophils in ischemic 
Table 3.  Laboratory Data
Control UTI
Preoperative Postoperative Preoperative Postoperative
WBC (10
3/mm
3)
Hemoglobin (g/dl)
AST (IU/L)
ALT (IU/L)
BUN (mg/dl)
Creatinine (mg/dl)
  7.2 ± 1.7
13.0 ± 2.0
19.4 ± 5.5
20.4 ± 11.4
14.0 ± 3.4
  0.9 ± 0.12
14.6 ± 4.6
11.5 ± 1.7
67.9 ± 57.6*
66.8 ± 58.8*
14.5 ± 4.3
  0.9 ± 0.2
  6.7 ± 1.4 
14.0 ± 1.8
28.5 ± 12.3
31.2 ± 15.7
13.5 ± 4.0
  0.9 ± 0.2
13.4 ± 6.3
11.9 ± 1.9
42.4 ± 17.6
67.5 ± 79.2
13.9 ± 3.7
  1.1 ± 0.5
Values are reported as the mean ± SD. UTI: urinary trypsin inhibitor. *P< 0.05 versus the preoperative group. 
Table 2.  Changes in IL-6 and IL-8 (pg/ml)
Time
IL-6 IL-8
Control UTI Control UTI
T0
T1
T2
T3
0
0
20.0 ± 9.4*
  45.7 ± 26.8*
0
0
   10.3 ± 4.2*,†
     20.7 ± 10.5*,†
0
0
  0.6 ± 0.5*
  0.8 ± 0.6*
0.1 ± 0.1
0.2 ± 0.2
1.2 ± 1.7
1.7 ± 3.1
Values are reported as the mean ± SD. UTI: urinary trypsin inhibitor. 
*P < 0.05 versus T0, 
†P< 0.05 versus the control. 337 www.ekja.org
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brain tissues [5,19,20]. UTI 100,000 units were used in this 
study. The routine clinical dose of UTI is 300,000 units [21], but 
a previous study showed that UTI 100,000 units was sufficient to 
attenuate the inflammation [22]. 
    All patients were injected with fentanyl 100-150 μg 
intravenously for pain control after surgery. It has been 
suggested that large doses of opioids may suppress the cytokine 
response to surgery, but conventional doses of opioids do not 
[23]. Furthermore, the consumption of fentanyl in both groups 
was similar. Therefore, the influence of fentanyl on the results at 
T3 was not considered. 
    Interestingly, the liver enzymes (AST, ALT) were elevated 
after surgery in the control group, but not in the UTI treatment 
group. The rise in liver enzymes indicates an intra-hepatic 
cause of liver dysfunction. The common etiologies of hepatic 
dysfunction in the perioperative period include sustained 
hypoxia or hypotension resulting in decreased hepatic blood 
flow, direct toxicity from drugs, hemolysis, and a worsening of 
preexisting liver disease [24]. These results showed that UTI 
must have had an effect on the post-operative liver enzyme 
levels. 
    In conclusion, UTI reduces the inflammatory responses to 
surgical stress by inhibiting IL-6 activation. However, further 
studies will be needed to examine its effect on the liver 
functions.
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